Inside this article
A useful treatment journal needs more detail than “I tried Ro.” The product in this entry is Ro Sparks: a fixed 55 mg sildenafil / 22 mg tadalafil sublingual preparation. Keeping that identity intact lets you distinguish a change in medicine from a change in packaging, service or expectations. The public records provide a starting point; they do not describe your eventual response.
Availability: Public product listing; individual eligibility and current prescription require confirmation.
The exact product
Create a baseline entry before comparing experiences. The distinctive feature of this offer is two PDE5 inhibitors in one prescription. Write the dispensed name and label details separately from the words in an advertisement. A future change in flavor, strength or ingredients can otherwise disappear behind the same familiar brand name. The fact record below identifies the reviewed listing without recommending a dose or telling you how to administer it.
| Provider | Ro |
|---|---|
| Listed active ingredients | Sildenafil + tadalafil |
| Dosage form | Compounded sublingual drop |
| Regulatory distinction | Compounded preparation; the finished product is not FDA-approved. |
| Source basis | Ro: ED product catalog and plan quantities · Ro: medication pricing · Ro: Sparks product details |
Price, supply and payment
The financial entry should record the payment date as well as the price. For Ro Sparks, the public starting point is $48 / 4 doses monthly. Keep a copy of the quantity and commitment attached to your own quote. If you later change products, this record helps distinguish a new prescription charge from a scheduled renewal. It also makes unused supply visible instead of treating every allocated dose as a successful treatment occasion.
| Monthly quantities | 4, 6, 8 or 10 allocated doses |
|---|---|
| Monthly charges | $48, $72, $96 or $120 respectively |
| Unit arithmetic | $12 per allocated dose; not a prescribed frequency |
| Timing limitation | Advertised onset is measured after dissolution, not necessarily from placement in the mouth |
What the research can support
Separate a research note from a personal observation. Here the published evidence concerns a 180-man trial of daily tadalafil plus as-needed sildenafil, not the Sparks sublingual formula; it leaves controlled finished-product onset and comparative safety unresolved. Your experience can be important to a clinician without becoming a controlled comparison. Likewise, a provider survey cannot tell you in advance how you will respond. Record the source and its limits beside the claim so that a memorable headline does not become the entire evidence entry.
| Evidence boundary | a 180-man trial of daily tadalafil plus as-needed sildenafil, not the Sparks sublingual formula |
|---|---|
| Not established here | controlled finished-product onset and comparative safety |
| Clinical and regulatory references | EAU: Management of erectile dysfunction · Cui et al. (2015): daily tadalafil with as-needed sildenafil · MedlinePlus: Tadalafil · DailyMed: Tadalafil prescribing information, including section 5.11 · FDA: Compounding and the FDA — questions and answers · MedlinePlus: Sildenafil |
Safety questions for the prescriber
The medication-history page belongs next to this product entry. Include other ED medicines, nitrates or nitrites, riociguat, blood-pressure treatment and medicines used only occasionally. Add relevant heart, kidney, liver or eye history. Do not experiment with overlaps or changes to isolate a side effect yourself. For a prescription such as Ro Sparks, an accurate account of what was taken and when is more useful than a guess about the ingredient responsible.
| Multiple PDE5 inhibitors | Standard tadalafil labeling advises against combining PDE5 inhibitors; individualized rationale and monitoring are needed. |
|---|
Availability and the actual prescription
Date the access information too. The current documentary finding is: Public product listing; individual eligibility and current prescription require confirmation. A product can remain mentioned online after its enrollment rules change. If an account message differs from an article, save both and ask which applies to the proposed prescription. Do not record a public listing as a completed eligibility decision, and do not mistake a pharmacy dispatch estimate for the whole clinical assessment period.
Refills, changes and cancellation
Keep follow-up entries factual: the original concern, the prescribed product, whether its directions were followed, and the response or unwanted effect. A useful prompt specific to this entry is “Why is this combination appropriate after reviewing my response to a single medicine?” Write down the clinician's answer and the plan for reassessment. Billing notes belong alongside this history but do not replace it; postponing a shipment is not necessarily a medical instruction to stop a treatment.
| Order cancellation | Contact support promptly during processing; shipped orders cannot be canceled or returned. |
|---|---|
| Prescription refunds | Generally final; dispensing errors and rejected treatment requests are separate cases. |
| Renewal notice | Use the cutoff disclosed for the selected subscription; no universal ED deadline was verified. |
| Clinical change | The support article states a response within two business days; not independently measured. |
| Policy sources | Ro: terms of use, payments and subscriptions · Ro Support: canceling an order · Ro Support: return and refund policy |
Compare named products
The neighboring reviews are useful for explaining what changed between two offers. Compare a formulation field or payment interval instead of collecting general brand impressions. If you discuss a switch, retain the old entry so the prescriber can see the sequence. Do not translate that sequence into a claim that one product is universally better: symptoms, instructions, concurrent medicines and expectations may have changed as well.
Questions to keep with the offer
A good record includes uncertainty. Mark an unverified current plan or missing study as unverified, rather than filling the space with a testimonial. This entry is based on public documents and is not medically reviewed. We have not obtained Ro Sparks as patients, inspected the supplied medicine or checked individual outcomes. The purpose is to make the next conversation more precise and the written history easier to use.
| Ask about this formula | Why is this combination appropriate after reviewing my response to a single medicine? |
|---|---|
| Ask about the payment | What are the exact quantity, total due now, renewal amount and notice deadline? |
| Ask about a change | Who confirms the medical instructions, pharmacy order and next account charge? |
When to get urgent help
An erection lasting more than four hours or chest pain requires emergency care. Tell the treating clinician what was taken and when.
Sudden hearing or vision loss needs prompt medical attention. Do not wait for an ordinary account-support reply.
Back to all individual product reviews
The sources behind this page
Public material checked October 7, 2026. Provider pages describe advertised products and terms; they do not independently establish treatment quality.
- Ro: ED product catalog and plan quantitiesProvider catalog; individual products, strengths and plan prices
- Ro: terms of use, payments and subscriptionsProvider policy; distinguish general subscription terms from Ro Body terms
- Ro Support: canceling an orderProvider support; processing orders and future shipments
- Ro Support: return and refund policyProvider support; prescription return and refund restrictions
- Ro Support: changing your prescriptionProvider support; clinical changes and follow-up
- EAU: Management of erectile dysfunctionSpecialty guideline; clinical evaluation, treatment, and limited combination evidence
- Cui et al. (2015): daily tadalafil with as-needed sildenafilPrimary clinical study; 180 patients, specific regimen, abstract reviewed via NCBI
- Ro: medication pricingProvider source; advertised plan prices and quantities
- Ro: Sparks product detailsProvider source; compounded formula, subscription pricing, and care process
- NIDDK: Diagnosis of erectile dysfunctionGovernment patient information
- MedlinePlus: TadalafilDrug information; standard tadalafil products
- DailyMed: Tadalafil prescribing information, including section 5.11Prescribing label; not evidence for the 4Play combination
- FDA: Compounding and the FDA — questions and answersGovernment guidance on compounded medications
- MedlinePlus: SildenafilDrug information; standard sildenafil products